Comprehensive Report on DYV-700/DYV702 for Acute Gout Pain

I. Introduction

DYV-700 is an investigational therapeutic agent formulated as a topical cream for transdermal administration, primarily developed for the management of pain associated with acute gout flares.[1] The development is spearheaded by Dyve Biosciences, Inc., a clinical-stage biotechnology company.[7] It is pertinent to note a nomenclature inconsistency within the source materials; the compound studied in the key clinical trial (NCT04130204) is referred to as both DYV-700 [2] and DYV702.[10] One source clarifies that DYV-700 and DYV-702 are alternative names for a sodium bicarbonate transdermal formulation.[18] This report will use "DYV-700/DYV702" to reflect this ambiguity while acknowledging they likely refer to the same entity. The primary therapeutic goal of DYV-700/DYV702 is to offer rapid pain relief and shorten the duration of acute gout attacks, addressing a significant unmet need in current gout management.[1]

II. Developer Profile: Dyve Biosciences and Technology Platform

Dyve Biosciences is a clinical-stage biotechnology company focusing on leveraging its proprietary transdermal delivery technology, known as the DMAX platform, across various therapeutic areas, including immunology and oncology.[10] A core scientific strategy for the company involves pH modulation, particularly targeting acidic microenvironments associated with disease progression in cancer and inflammatory conditions.[26]

The DMAX platform is central to Dyve's approach. It is described as an innovative emulsion technology designed to enhance the penetration of therapeutic agents through the skin.[6] The proposed mechanism involves transiently and reversibly fluidizing the skin's lipid matrix and modulating tight junctions upon topical application.[27] This process is intended to facilitate the non-destructive delivery of molecules, potentially including those that are typically unsuitable for oral or injectable routes or cannot easily cross epithelial barriers (e.g., molecules outside Lipinski's Rules).[27] Dyve Biosciences promotes this technology as enabling rapid onset of action and systemic availability comparable to injection, combined with the convenience of a topical application, positioning it as a potential "universal third route of drug delivery".[20]

The company's strategy appears platform-centric, applying the DMAX technology to different therapeutic targets and disease areas. Besides the gout program (DYV-700/DYV702), the pipeline includes DYV800, a pH-modulating agent targeting tumor microenvironment (TME) acidity in solid tumors (preclinical stage, in collaboration with Moffitt Cancer Center) [8], and DYV600 for melasma, described as being in advanced clinical programs.[6] The development of DYV-700/DYV702 for gout exemplifies the application of Dyve's pH modulation strategy, using the DMAX platform to deliver an alkalinizing agent locally to the affected joint.[3] This approach circumvents the challenges associated with systemic delivery of pH modulators, such as the gastrointestinal intolerance observed with oral alkalinizing agents at doses needed for therapeutic effect.[27] The feasibility and potential efficacy of DYV-700/DYV702 are thus intrinsically linked to the successful functioning of the DMAX delivery system.

III. DYV-700/DYV702: Mechanism of Action in Gout

DYV-700/DYV702 is specifically developed to treat the pain associated with acute gout flares.[1] Gout affects a significant population, estimated at over 10 million in the U.S., with a substantial portion experiencing recurrent attacks.[6] Current standard-of-care treatments for acute flares, such as colchicine and NSAIDs [20], often take days to provide relief and can be associated with adverse events like gastrointestinal distress.[6] DYV-700/DYV702 aims to address this unmet need by providing faster and potentially better-tolerated pain relief.[1]

The therapeutic is administered topically as a cream, described as having the consistency of a moisturizer or lotion, applied directly to the skin over the affected joint during an acute flare, typically three times daily.[3]

The proposed mechanism of action is distinct from traditional systemic anti-inflammatory agents. It relies on the DMAX platform to facilitate the rapid transdermal delivery of the active component, sodium bicarbonate [18], into the joint space.[3] Once delivered locally, the sodium bicarbonate acts as a pH modulating agent [26], neutralizing the acidic microenvironment within the joint.[3] This localized increase in pH is hypothesized to directly dissolve the monosodium urate (MSU) crystals, which are the underlying cause of the inflammation and intense pain characteristic of gout flares.[3] By targeting the crystals directly at the site of inflammation, DYV-700/DYV702 aims to provide rapid pain relief, potentially within minutes or hours rather than days, and to shorten the overall duration of the gout attack.[1] This localized, mechanism-based approach represents a potential shift from managing the inflammatory symptoms systemically to directly addressing the crystal pathology within the joint.[6]

IV. Clinical Development Program

A. Early Clinical and Preclinical Data

Prior to initiating Phase 2 studies, Dyve Biosciences conducted preclinical work and a pilot clinical study. Pharmacokinetic (PK) data from the DMAX platform suggested the potential for rapid drug delivery, described as "injection-like".2 A pilot study in patients with acute gout flares yielded encouraging results, which were presented at scientific meetings including the American College of Rheumatology (ACR) Annual Meeting in 2019 6 and a European Crystal Network Workshop in 2019.8 This pilot study reportedly showed that DYV-700/DYV702 provided meaningful and statistically significant pain reduction (p=0.004) within minutes of application, and reduced the duration of gout attacks by nearly 50% compared to a control group.2 The treatment was also reported to be safe and well-tolerated in this initial study.6 These positive preliminary findings provided the rationale for advancing DYV-700/DYV702 into Phase 2 development.2

B. Phase 2 TARGETS Study (NCT04130204)

The pivotal clinical evaluation of DYV-700/DYV702 documented in the provided materials is the Phase 2 TARGETS study.

• Regulatory Status and Timeline: Dyve Biosciences received clearance from the U.S. Food and Drug Administration (FDA) to proceed with the Phase 2 trial in December 2019.[5] The trial was initiated in the first quarter of 2020 [5], with the first patient enrolled in February 2020.[2] The study status is listed as "Completed" in some database sources.[7] Key results were presented in a podium presentation at the EULAR (European Alliance of Associations for Rheumatology) Congress in June 2022.[19] However, a drug pipeline database snapshot dated April 2025 lists the status for DYV-700 in Pain as "Pending," creating ambiguity about its current standing.[28]
• Study Design: TARGETS (NCT04130204) was designed as a randomized, double-blind, placebo-controlled, parallel-group study conducted across 20 centers in the United States.[1] The treatment duration was 7 days.[20]
• Participants and Enrollment: The study enrolled patients experiencing an acute gout flare.[1] The initially planned enrollment was 300 subjects.[1] However, the results presented at EULAR 2022 were based on 98 randomized patients comprising the Full Analysis Set (FAS).[20] A Per Protocol (PP) population of 57 patients was also analyzed, with the difference attributed primarily to nonadherence on Day 1.[20] This discrepancy between planned and actual enrollment is substantial (98 vs. 300) and suggests potential recruitment difficulties or other unstated factors affecting the trial's execution. The significant rate of nonadherence (approx. 42% excluded from PP analysis) also warrants consideration when interpreting the results.
• Interventions: Patients were randomized to receive either topical DYV702 (sodium bicarbonate cream) or a matching placebo cream.[20] Crucially, upon experiencing a flare onset, all participants were instructed to initiate standard-of-care treatment with oral colchicine (1.2 mg followed by 0.6 mg one hour later) in addition to applying the assigned study cream.[20] Therefore, the study evaluated the efficacy of DYV702 as an adjunct to initial colchicine therapy compared to placebo plus initial colchicine therapy.
• Objectives and Endpoints: The primary objectives initially stated were to evaluate the efficacy of DYV-700 in reducing pain intensity and the duration of the gout attack.[1] The EULAR 2022 presentation abstract title listed treatment-emergent adverse events as the primary endpoint [22], while the presentation itself focused on pain-related efficacy endpoints over the 7-day treatment period.[20] Key secondary endpoints reported at EULAR included time to pain resolution (defined as ≥50% reduction from baseline), use of rescue pain medication, physical function assessment using PROMIS PF20, patient global assessment, and physician assessments of joint tenderness and swelling.[20]
• Efficacy Results (EULAR 2022): The results presented emphasized benefits observed within the first 24 hours of treatment.[20]
• Per Protocol Population (n=57):
• Median time to pain resolution (≥50% reduction): 24 hours for DYV702 vs. 72 hours for placebo (p=0.03).
• Responder rate at 24 hours: 58% for DYV702 vs. 24% for placebo (p=0.01).
• Full Analysis Set (n=98):
• Rescue medication usage: Significantly lower in the DYV702 group (6.3%) compared to placebo (20%) (p=0.02).
• Physical function (PROMIS PF-20): Significantly greater improvement at 24 hours with DYV702 (score 16.7) vs. placebo (score 9.4) (p<0.01). This difference reportedly persisted through Day 7.
• Safety Results: Detailed safety data, including specific adverse event rates or types from the TARGETS study, are not available in the provided snippets.[34] Pilot study data suggested good tolerability.[6] The EULAR 2022 abstract title implied safety was a primary outcome measure [22], and safety endpoints were assessed [20], but the specific findings were not captured in the available text.

Table 1: Summary of Phase 2 TARGETS Study (NCT04130204)

V. Current Status and Future Outlook

The most advanced clinical milestone reported for DYV-700/DYV702 is the completion of the Phase 2 TARGETS study (NCT04130204) [7], with positive efficacy results focused on rapid pain relief presented at the EULAR Congress in June 2022.[19] Based on these findings, Dyve Biosciences indicated that future pivotal studies might focus on a 24-hour primary endpoint to capture the rapid onset of action observed.[20]

However, the current development status beyond this Phase 2 data presentation is unclear based on the provided information. There are no press releases or updates within the supplied documents confirming the initiation of a Phase 3 trial or providing further development updates for the gout program after June 2022.[4] Compounding this ambiguity, a drug pipeline database snapshot from April 2025 lists DYV-700's status for the indication 'Pain' as "Pending," which contrasts with the earlier reports of Phase 2 completion.[28] This discrepancy raises questions about whether the program is actively progressing towards Phase 3, has been paused, or potentially deprioritized.

Meanwhile, Dyve Biosciences continues to highlight its DMAX platform and advance other pipeline candidates. Notably, news from April 2023 focused on the presentation of preclinical data for their oncology asset, DYV800, developed in collaboration with Moffitt Cancer Center.[8] The relative recency of news flow concerning the oncology program compared to the gout program could suggest a possible shift in the company's strategic focus or resource allocation, although this remains speculative based solely on the timing of the information provided. The broader landscape for gout therapeutics includes several candidates from other companies progressing through late-stage development.[9]

VI. Conclusion

DYV-700/DYV702 represents a novel therapeutic approach for the management of acute gout flare pain, developed by Dyve Biosciences. Its distinction lies in its topical administration route, enabled by the proprietary DMAX transdermal delivery platform, and its unique mechanism of action, which involves localized pH modulation via sodium bicarbonate to dissolve causative MSU crystals within the affected joint.[3]

Clinical development reached the completion of a Phase 2 study (TARGETS, NCT04130204), which demonstrated statistically significant and clinically meaningful reductions in pain intensity and improvements in physical function within the first 24 hours of treatment, when used adjunctively with standard initial colchicine therapy.[20] These findings support the potential for DYV-700/DYV702 to offer a rapid-acting, localized treatment option, potentially addressing the unmet need for faster pain relief in acute gout flares compared to existing systemic therapies.[1]

Despite the positive Phase 2 results presented in mid-2022, the current development status of DYV-700/DYV702 is uncertain based on the information available in the provided documents. The lack of subsequent news regarding Phase 3 initiation and conflicting status reports from pipeline databases [28] leave the program's future trajectory unclear. Further information would be required to ascertain whether Dyve Biosciences is actively advancing DYV-700/DYV702 towards later-stage development and potential market entry.

Works cited

1. What's the latest update on the ongoing clinical trials related to Gout?, accessed May 2, 2025, https://synapse.patsnap.com/article/whats-the-latest-update-on-the-ongoing-clinical-trials-related-to-gout
2. Dyve Biosciences Announces First Patient Enrolled in TARGETS Study for Treatment of Acute Gout - BioSpace, accessed May 2, 2025, https://www.biospace.com/dyve-biosciences-announces-first-patient-enrolled-in-targets-study-for-treatment-of-acute-gout
3. Dyve Biosciences enrolls first patient in gout trial - MassDevice, accessed May 2, 2025, https://www.massdevice.com/dyve-biosciences-enrolls-first-patient-in-gout-trial/
4. Medical Design & Outsourcing — MAY 2021 by WTWH Media LLC - Issuu, accessed May 2, 2025, https://issuu.com/wtwhmedia/docs/mdo_may21_vs1
5. Dyve Biosciences wins FDA nod for Phase 2 transdermal drug delivery trial - MassDevice, accessed May 2, 2025, https://www.massdevice.com/dyve-biosciences-wins-fda-nod-for-phase-2-transdermal-drug-delivery-trial/
6. Dyve Biosciences Receives FDA Clearance to Begin Phase 2 Study of DYV-700 for Treatment of Acute Gout Pain, accessed May 2, 2025, https://dyvebio.com/press-release/dyve-biosciences-receives-fda-clearance-to-begin-phase-2-study-of-dyv-700-for-treatment-of-acute-gout-pain/
7. DYV-700 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 2, 2025, https://synapse.patsnap.com/drug/aa8eedf16afc4dd3a815e9964f313765
8. Dyve Biosciences - 2025 Company Profile, Funding & Competitors - Tracxn, accessed May 2, 2025, https://tracxn.com/d/companies/dyve-biosciences/__Ao0YiDLE2ykDiqMZRcArh5dib0zyhjxMamxcfuAfpOc
9. DelveInsight Estimates a Promising Gout Pipeline Owing to an Expected Entry of Novel Therapeutic Agents - GlobeNewswire, accessed May 2, 2025, https://www.globenewswire.com/news-release/2021/09/01/2289609/0/en/DelveInsight-Estimates-a-Promising-Gout-Pipeline-Owing-to-an-Expected-Entry-of-Novel-Therapeutic-Agents.html
10. Press Release - Dyve Biosciences, accessed May 2, 2025, https://dyvebio.com/category/press-release/page/2/
11. Dyve Biosciences Announces Chuck Harbert, Ph.D. to Join as Chief Scientific Officer, accessed May 2, 2025, https://dyvebio.com/press-release/dyve-biosciences-announces-chuck-harbert-ph-d-to-join-as-chief-scientific-officer/
12. Dyve Biosciences hires new chief scientific officer - MassDevice, accessed May 2, 2025, https://www.massdevice.com/dyve-biosciences-hires-new-chief-scientific-officer/
13. Top 20 Intact skin companies - Discovery|PatSnap, accessed May 2, 2025, https://discovery-patsnap-com.libproxy.mit.edu/topic/intact-skin/
14. Recon: Sanofi Exits Diabetes Research; South Korea Convicts Three Samsung Execs for Destroying Evidence | RAPS, accessed May 2, 2025, https://www.raps.org/news-and-articles/news-articles/2019/12/recon-sanofi-exits-diabetes-research-south-korea
15. Dyve Biosciences Announces First Patient Enrolled in TARGETS Study for Treatment of Acute Gout - Business Wire, accessed May 2, 2025, https://www.businesswire.com/news/home/20200220005195/en/Dyve-Biosciences-Announces-First-Patient-Enrolled-in-TARGETS-Study-for-Treatment-of-Acute-Gout
16. Dyve Biosciences appoints Camilla V. Simpson to its board - Drug, accessed May 2, 2025, https://www.drugdeliverybusiness.com/dyve-biosciences-appoints-camilla-v-simpson-to-its-board/
17. Top 20 Iron deficient companies - Discovery|PatSnap, accessed May 2, 2025, https://discovery-patsnap-com.libproxy.mit.edu/topic/iron-deficient/
18. Sodium bicarbonate transdermal - Dyve Biosciences - AdisInsight - Springer, accessed May 2, 2025, https://adisinsight.springer.com/drugs/800056837
19. DYV-700 - FirstWord Pharma, accessed May 2, 2025, https://firstwordpharma.com/river/tag/fw_product/DYV-700
20. Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702 for Pain Associated with Acute Gout Flares Showcased in Podium Presentation at 2022 EULAR Congress - BioSpace, accessed May 2, 2025, https://www.biospace.com/dyve-biosciences-announces-phase-2-targets-study-of-dyv702-for-pain-associated-with-acute-gout-flares-showcased-in-podium-presentation-at-2022-eular-congress
21. Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702 for Pain Associated with Acute Gout Flares Showcased in Podium Presentation at 2022 EULAR Congress - GlobeNewswire, accessed May 2, 2025, https://www.globenewswire.com/news-release/2022/06/01/2454568/0/en/Dyve-Biosciences-Announces-Phase-2-TARGETS-Study-of-DYV702-for-Pain-Associated-with-Acute-Gout-Flares-Showcased-in-Podium-Presentation-at-2022-EULAR-Congress.html
22. Clinical Catch-Up: NIH's COVID-19 Trial and All About ASCO - BioSpace, accessed May 2, 2025, https://www.biospace.com/clinical-catch-up-may-30-june-3
23. 34th Annual ROTH Conference - March 13-15, 2022 - Events, accessed May 2, 2025, https://events.investorbrandnetwork.com/2022/roth/
24. Gouty Arthritis Pipeline Drugs Market by Stages, Target and Key Players - GlobalData, accessed May 2, 2025, https://www.globaldata.com/store/report/gouty-arthritis-gout-drugs-in-development-analysis/
25. Phase II | Rheumatology | Pipeline Prospector - PharmaCompass.com, accessed May 2, 2025, https://www.pharmacompass.com/pipeline-prospector-drugs-in-development/rheumatology/phase-ii
26. Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting - Business Wire, accessed May 2, 2025, https://www.businesswire.com/news/home/20230424005377/en/Dyve-Biosciences-Presents-Preclinical-Data-from-Lead-Oncology-Drug-Candidate-DYV800-at-the-American-Association-for-Cancer-Research-2023-Annual-Meeting
27. Dyve Biosciences: Our science is anything but basic, accessed May 2, 2025, https://dyvebio.com/
28. Dyve Biosciences, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed May 2, 2025, https://synapse.patsnap.com/organization/de2c2321fb8377a80b7e191ff7085d7a
29. Gout Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034, accessed May 2, 2025, https://www.researchandmarkets.com/reports/5969758/gout-market-epidemiology-industry-trends
30. Gout Market Size, Share & Forecast Report 2025-2035 - IMARC Group, accessed May 2, 2025, https://www.imarcgroup.com/gout-market
31. (PDF) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) - ResearchGate, accessed May 2, 2025, https://www.researchgate.net/publication/7073216_EULAR_evidence_based_recommendations_for_gout_Part_II_Management_Report_of_a_task_force_of_the_EULAR_Standing_Committee_for_International_Clinical_Studies_Including_Therapeutics_ESCISIT
32. 8 drug delivery innovations you need to know - Page 3 of 9, accessed May 2, 2025, https://www.drugdeliverybusiness.com/8-drug-delivery-innovations-you-should-know-2020/3/
33. Colchicine Completed Phase 2 Trials for Gout Flares Treatment | DrugBank Online, accessed May 2, 2025, https://go.drugbank.com/drugs/DB01394/clinical_trials?conditions=DBCOND0059958&phase=2&purpose=treatment&status=completed
34. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT04130204
35. accessed January 1, 1970, https://classic.clinicaltrials.gov/ct2/show/NCT04130204
36. The US government does not review or approve the safety and science of all studies listed on this website. - Error | ClinicalTrials.gov, accessed May 2, 2025, https://clinicaltrials.gov/search?term=NCT00506883%20NCT00819585%20NCT01399008%20NCT01994226%20NCT02060552%20NCT02063997%20NCT02139046%20NCT02330796%20NCT02500641%20NCT03131583%20NCT04130204%20NCT05324423%20NCT05698680
37. Dyve Biosciences Announces Chuck Harbert, Ph.D. to Join as Chief, accessed May 2, 2025, https://www.biospace.com/dyve-biosciences-announces-chuck-harbert-ph-d-to-join-as-chief-scientific-officer
38. Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - MarketResearch.com, accessed May 2, 2025, https://www.marketresearch.com/Global-Markets-Direct-v3480/Gouty-Arthritis-Gout-Drugs-Development-32817670/
39. Gout - Pipeline Insight, 2025 - Research and Markets, accessed May 2, 2025, https://www.researchandmarkets.com/reports/5262015/gout-pipeline-insight-2025